(HealthDay)—For patients with stage 4 or 5 chronic kidney disease and hepatitis C virus (HCV) infection, 12 weeks of treatment with glecaprevir and pibrentasvir results in a high rate of sustained virologic response, according ...
Oct 12, 2017
0
0
In a recent study, screening rates for hepatitis C virus (HCV) infection among baby boomers increased fivefold in the year following implementation of an electronic health record (EHR)-based prompt for primary care physicians. ...
Sep 15, 2017
0
1
A new study indicates that direct-acting antiviral therapy is safe and effective in patients with chronic kidney disease (CKD) and Hepatitis C virus (HCV) infection. The study, which appears in an upcoming issue of the Clinical ...
Sep 7, 2017
0
5
Globally, an estimated 71 million people are living with chronic hepatitis C virus (HCV). Over decades of infection, chronic HCV infection results in progressive damage to the liver and an increased risk for end stage liver ...
Jun 8, 2017
0
20
FDA-approved oral direct-acting antiviral (DAA) regimens produce high sustained virologic response (SVR) rates for all six hepatitis C virus (HCV) genotypes and for patient populations historically considered difficult to ...
Mar 20, 2017
0
0
Data suggest that several commercially available tests for hepatitis C virus core antigen (HCVcAg) are highly sensitive and specific and could transform the current two-test screening process for HCV into a single test. A ...
Jun 20, 2016
0
1
An international team of researchers has shed light on the potential impact of new drugs for hepatitis C virus (HCV).
May 18, 2016
0
3
Hepatitis C virus (HCV) hijacks the host's fat metabolism for its own survival, growth, and transport in the human body. A study published on April 28th in PLOS Pathogens identifies a host gene involved in the formation of ...
Apr 28, 2016
0
5
Hepatitis C virus (HCV) is a small, enveloped virus comprising an RNA genome encased in a protein capsid and surrounded by a lipid bilayer containing two glycoproteins. Acute infection can cause hepatitis but the virus usually ...
Mar 31, 2016
0
2
(HealthDay)—The total medical costs associated with interferon (IFN)-based antiviral treatment among patients with chronic hepatitis C virus (HCV) infection average €14,559, with a mean cost of €38,514 per sustained ...
Mar 24, 2016
0
3
